Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer molecular libraries

Other drug agents

Bio-reagents and biochemicals

MedKoo's

Anticancer molecular libraries

Hypoxia cytotoxic agent library

Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. (source: Nat Rev Cancer. 2011 Jun;11(6):393-410.)

Apaziquone （EO9） (bioreductive prodrug, hypoxia toxic agent)

Banoxantrone (AQ4N) (bioreductive prodrug, hypoxia toxic agent)

Chlorambucil N-oxide

Doranidazole （PR-350)

Elesclomol (HSP-90 Inhibitor)

Etanidazole (SR-2508)

KS119W  (bioreductive prodrug)

KU-2285 (hypoxic cell sensitizer)

LW6 (HIF-1α inhibitor)

Misonidazole

Nimorazole

NLCQ-1(bioreductive prodrug)

NSC 639862

Porfiromycin

PR-104 (bioreductive prodrug)

PX-478 (HIF-1α inhibitor)

RB 6145 （CI-1010)

RH1 (bioreductive prodrug)

RU 1069

Sanazole (AK2123)

SN29730  (bioreductive prodrug)

SN30000  (CEN-209) bioreductive prodrug)

Tretazicar (CB1954) (bioreductive prodrug)

TH-302  (bioreductive prodrug)

Tirapazamine (bioreductive prodrug)

TX-2120

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)